Quote:

---

A total of 2,022 patients were randomly selected to receive tocilizumab, which is marketed under the brand name Actemra, by intravenous infusion and were compared with 2,094 patients randomly selected to receive standard care alone. The researchers said 82% of the patients were also taking a steroid such as dexamethasone, another drug that has been found to reduce deaths in the sickest Covid-19 patients.

Researchers said 596 patients in the tocilizumab group died within 28 days compared with 694 patients in the standard care group. That means for every 25 patients treated with tocilizumab, “one additional life would be saved,” Oxford researchers said.

---

Interesting, death rates 28 days:

Tocilizumab group: 596/2022= 29.5%
Standard Care: 694/2094= 33.14%
Overall: =(694+596)/(2094+2022) = 31.34%

Sounds familiar ??? It should !!!

Now. Overall for Vyrologix: 22.31%

I say: "we are cooking with gas"